RxDoctor Payments Data

Herminia Hawkins

Adult Health · Bakersfield, CANPI 1245647619

Payments from drug & device makers

$1,558in general payments, 2019–2025

Across 78 payments — averaging $19.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$356
  • Novo Nordisk$183
  • Amgen$161
  • GSK$126
  • Lilly USA, LLC$87
  • AstraZeneca$63
  • plus $582 from 19 others

What the payments were for

  • Food & beverage$1,558100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,558 in reported general payments places this provider in the 75th percentile of 785 adult health providers in California.

See all adult health providers in California

Medicare billing

Part B allowed, 2024
$140
Medicare patients
11
Services billed
16

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide36$36,708
TradjentaLinagliptin25$17,716
OzempicSemaglutide14$14,274
Albuterol Sulfate HfaAlbuterol Sulfate39$1,274
Atorvastatin Calcium152$985
Ezetimibe22$929
Gabapentin49$688
Ipratropium Bromide14$549
Levothyroxine Sodium40$520
Ondansetron OdtOndansetron22$408
Lisinopril73$393
Metformin Hcl54$377
Baclofen13$371
Tamsulosin Hcl15$367
Metoprolol Succinate16$341

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$87$36,70836 claims
Boehringer IngelheimTradjenta$23$17,71625 claims
Novo NordiskOzempic$183$14,27414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 785 adult health providers in California.

Other adult health in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →